A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

Summary

A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic Fibrosis will be included in the study.

Timeline

Start

2019-05-16

Primary completion

2020-03-11

Completion

2021-07-10

Outcome

Outcome not reported

Stopped: “Futility”

Drugs

Indications